AQS — Aequus Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Aequus Replaces Expired Short Form Base Shelf Prospectus
Brief: Aequus Signs Exclusive Distribution Agreement With Medicom Healthcare For Canadian Distribution Rights Of Ophthalmic Products
Brief: Aequus To Supply Kensington Eye Institute With Zepto Capsulotomy System Extends Distribution Agreement With Mynosys
Brief: Aequus Signs Term Sheet For Five Preservative Free Dry Eye Products
Brief: Aequus Signs Term Sheet With European Partner For Preservative Free Therapeutic In Ophthalmology
Brief: Aequus Announces Expansion Of Market Opportunity For Its Long Acting Anti-Nausea Transdermal Patch
Brief: Aequus Extends And Enhances Commercial Agreement To Promote Vistitan In Canada
Brief: Aequus Receives Positive FDA Regulatory Guidance For Anti-Nausea Patch
Brief: Aequus And Camargo Complete Pre-Investigational New Drug Submission With FDA For Transdermal Anti-Nausea Program
Brief: FDA Confirms Date To Providing Regulatory Guidance For Aequus’ Anti-Nausea Patch
Brief: Aequus And Ehave Enter Into Collaboration Agreement
Brief: Aequus And Camargo To Meet FDA To Advance Anti-Nausea Patch
Brief: Cannaroyalty And Aequus Pharmaceuticals Announce JV To Develop And Commercialize Cannabis-Based Therapies Targeting Neurological Disorders
Brief: Aequus Posts Q3 Revenue Of $291,154
Brief: Aequus announces positive results for proof of concept clinical trial of anti-nausea patch
Brief: Ehave, Aequus enters into a collaboration
Brief: Aequus Pharma received positive feedback from FDA to pursue AQS1301
Brief: Aequus receives approval for short form base shelf prospectus to raise up to C$20 mln
Brief: Aequus and Scientus agree to collaborate for a medical Cannabis commercial supply and product development